Latest Research Report on Ebola Virus Vaccine
The Global Ebola Virus Vaccine Market reached US$ 173.82 million in 2024 and is expected to reach US$ 288.41 million by 2033, growing at a CAGR of 6.4 % during the forecast period 2025-2033.
Ebola Virus Vaccine is a medical solution designed to protect individuals from the Ebola virus, a deadly disease that causes severe hemorrhagic fever. The vaccine works by stimulating the immune system to recognize and fight the virus, preventing infection in case of exposure.
The Ebola virus has caused several devastating outbreaks, primarily in Africa, and has a high mortality rate. In response, researchers have developed vaccines to control the spread of the virus and protect those at risk, such as healthcare workers and individuals in outbreak areas. One of the most well-known vaccines, rVSV-ZEBOV, has shown promising results in clinical trials and is approved for use in preventing Ebola. The development of these vaccines represents a major step forward in global health, offering hope for preventing future outbreaks and saving lives.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/ebola-virus-vaccine-market
Market Growth Drivers:
Rising Incidence of Ebola
According to the World Health Organization (WHO) data from August 2023, two monoclonal antibody treatments for Ebola are highly recommended: mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb), both of which have proven to be effective in treating the virus. The average fatality rate for Ebola is around 50%, although it has ranged from 25% to 90% in past outbreaks, depending on the specific situation and response efforts.
In March 2023, AIM ImmunoTech Inc. began exploring Ampligen (rintatolimod) as a potential preventive treatment for early-onset Ebola outbreaks. New research shows that Ampligen may effectively inhibit the spread and replication of the Ebola virus, further supporting its potential use in combating the disease. Ampligen, a broad-spectrum immuno-modulator, is also being studied for treating various cancers, viral infections, and immune disorders. In mouse models, Ampligen provided 100% protective benefits against Ebola at doses that can be easily achieved in humans. Additionally, the growing demand for expanded immunization programs is further driving the growth of the global Ebola virus vaccine market.
Stringent Regulatory Approval
After clinical trials, vaccines must undergo a detailed review by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the World Health Organization (WHO). These agencies evaluate whether the vaccine meets the required safety, efficacy, and manufacturing standards. During Ebola outbreaks, some regulatory bodies may grant Emergency Use Authorizations (EUAs) or accelerated approvals to speed up vaccine availability.
However, even these fast-tracked processes still involve thorough regulatory oversight and additional steps to ensure the vaccine is safe and effective in emergency situations. These factors could potentially limit the growth of the global Ebola virus vaccine market.
Market Segments:
- By Strain Type: Zaire Ebolavirus, Sudan Virus, Taï Forest Virus, Others
- By Vaccine Type: rVSV-ZEBOV, Ad26.ZEBOV and MVA-BN-Filo, Others
- By End-User: Hospitals, Specialty Clinics, Others
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Key Players:
- Johnson & Johnson
- Merck & Co., Inc.
- GSK plc.
- CansinoBl0
- AIM ImmunoTech Inc.
Customize Your Scope: https://www.datamintelligence.com/customize/ebola-virus-vaccine-market
Regional Growth
North America is expected to maintain a strong share in the global Ebola virus vaccine market.
The North American Ebola virus vaccine market plays a crucial role in the global fight against Ebola, especially in research, development, and preparedness. Although the region has not experienced large-scale Ebola outbreaks, its advanced healthcare infrastructure and research capabilities are key to vaccine development.
U.S. agencies like the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have been pivotal in funding Ebola vaccine research, clinical trials, and preparedness efforts. Moreover, the U.S. government has supported global health initiatives to address Ebola outbreaks through the U.S. Agency for International Development (USAID) and partnerships with organizations like the World Health Organization (WHO).
In August 2023, the U.S. Food and Drug Administration (FDA) expanded the approved use of Merck’s ERVEBO vaccine to include children as young as 12 months old. The vaccine is now authorized to prevent disease caused by the Zaire ebolavirus in individuals aged 12 months and older, whereas it was previously only approved for those 18 years and older.
Asia Pacific is growing at the fastest pace in the global ebola virus vaccine market share
APAC countries are working closely with global health organizations and governments to tackle health emergencies. Key players like the World Health Organization (WHO), the Global Health Security Agenda (GHSA), and the Bill & Melinda Gates Foundation play a vital role in providing funding, research, and support for the distribution of Ebola vaccines in the region. Countries across APAC are uniting to strengthen their healthcare systems and improve their response capabilities. These collaborations not only boost vaccine access but also enhance distribution efforts throughout the region.
In May 2024, RedHill Biopharma announced it had been granted a new patent in China for opaganib as a treatment to inhibit the replication of single-stranded RNA viruses, including the Ebola virus. This patent, which is valid until 2035, further strengthens the company’s intellectual property portfolio.
Key Developments
In June 2024, Gavi, the Vaccine Alliance, unveiled new programs to introduce four additional vaccines in the countries it supports: preventive Ebola, human rabies (for post-exposure treatment), multivalent meningococcal conjugate, and the hepatitis B birth dose. These programs, which had previously been approved by the Gavi Board, were delayed due to the recent pandemic.
